Monte Rosa says Novartis starts Phase 2 trial of MRT-6160 in Sjögren's disease, triggers USD 50 million milestone

• Novartis initiated a Phase 2 study of VAV1-directed molecular glue degrader MRT-6160 (DDY391) in Sjögren’s disease.
• Monte Rosa will receive a USD 50 million milestone tied to the study’s first patient visit.
• No new trial results were presented; the study will assess whether MRT-6160 can improve disease outcomes while remaining safe and tolerable.
• The trial is designed to support Phase 3 dose selection, reinforcing the program’s progression under the Novartis license.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Monte Rosa Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609080700PRIMZONEFULLFEED9821727) on September 08, 2026, and is solely responsible for the information contained therein.